Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo and Active-controlled, Parallel-group, Multicentre Clinical Study

Trial Profile

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo and Active-controlled, Parallel-group, Multicentre Clinical Study

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Opicapone (Primary) ; Benserazide; Carbidopa; Entacapone; Levodopa
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms BIPARK-I
  • Sponsors Bial
  • Most Recent Events

    • 26 Jul 2017 Montenegro and Netherlands were planned locations for this study.
    • 27 Jun 2017 Results assessing ease of switch from this trial presented at the 3rd Congress of the European Academy of Neurology
    • 27 Jun 2017 Results from 1-year, open-label part of this trial presented at the 3rd Congress of the European Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top